EHA congress presentation on June 13 may generate attention; watch for any partnership or licensing interest that could validate the platform and extend cash runway. No IND filed yet, clinical testing timeline remains the key catalyst to monitor.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jun 11 $3.61entry
- T+1 · 5mo ago +0.83%α +0.29% · $3.64
- T+5 · 5mo ago −8.03%α −8.47% · $3.32
- T+20 · 4mo ago −11.36%α −13.25% · $3.20
- T+60 · 2mo ago −13.57%α −17.97% · $3.12
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Evaxion announced new preclinical data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia, showing successful expression/secretion in human cells and specific immune responses with targeted cell-killing. Data will be presented at the EHA 2026 Congress on June 13. This is an early-stage, non-clinical milestone for a pre-revenue biotech with no financial figures or regulatory filing trigger, making it a modest positiveEntwicklung but not a material near-term catalyst.
Key Facts
- EVX-04, an off-the-shelf therapeutic vaccine for AML, achieved complete expression and secretion in human cells, enabling immune recognition and activation
- All 16 ERV antigen fragments included in EVX-04 drive specific immune responses in mice (in vivo) and human cells (in vitro) and induce targeted cell-killing
- Poster presentation at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden on June 13, 2026
- Company states it is preparing regulatory filing for clinical testing
- AML has ~25% 3-year overall survival for elderly patients ineligible for intensive treatment, signaling high unmet need
Financial Impact
No financial figures reported; pre-revenue clinical-stage company. Potential future value depends on successful IND filing and eventual clinical data
Risk Factors
- EVX-04 is pre-clinical; no human efficacy or safety data yet and regulatory filing for clinical testing has not been submitted
- Preclinical results may not translate to clinical success; AML is a competitive space with existing immunotherapies
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-004043 |
| Document: f6k_061026.htm | 0001171843-26-004043 |
| Document: 0001171843-26-004043-index-headers.html | 0001171843-26-004043 |
| Document: 0001171843-26-004043-index.html | 0001171843-26-004043 |
| Document: 0001171843-26-004043.txt | 0001171843-26-004043 |
Track record
50 reports on EVAX
6 of 10 bullish or bearish reports moved the stock their way by T+1. Best: +22.94% at T+5 after the Mar 5, 2026 report. 9 of 10 went positive at some point.
Filters
- Nov 12, 20264d ago 6-K Neutral 2/10 Entry $2.77 to $2.74 Now $2.77 −0.00% ▼ −1.08% −0.72% vs SPY
- Nov 12, 20264d ago Press Release Neutral 1/10 Entry $2.77 to $2.74 Now $2.77 −0.00% ▼ −1.08% −0.72% vs SPY
- Nov 9, 20267d ago 6-K / F-1/A / PRESS-RELEASE Neutral 3/10 Entry $2.75 to $2.86 Now $2.77 +0.73% ▲ +4.00% +4.37% vs SPY
- Nov 6, 202610d ago 6-K Neutral 4/10 Entry $3.00 to $2.75 Now $2.77 −7.67% ▼ −8.33% −10.70% vs SPY
- Nov 6, 202610d ago Press Release Neutral 4/10 Entry $3.00 to $2.75 Now $2.77 −7.67% ▼ −8.33% −10.70% vs SPY
- Nov 4, 202612d ago 6-K Neutral 3/10 Entry $2.97 to $2.76 Now $2.77 −6.73% ▼ −7.07% −2.66% vs SPY
- Nov 4, 202612d ago 6-K Neutral 3/10 Entry $2.97 to $2.76 Now $2.77 −6.73% ▼ −7.07% −2.66% vs SPY
- Nov 3, 202613d ago 6-K Neutral 4/10 Entry $2.96 to $2.97 Now $2.77 −6.42% ▲ +0.34% −1.31% vs SPY
- Oct 30, 202617d ago 6-K Neutral 2/10 Entry $2.93 to $2.92 Now $2.77 −5.46% ▼ −0.34% +0.14% vs SPY
- Oct 30, 202617d ago Press Release Neutral 3/10 Entry $2.93 to $2.92 Now $2.77 −5.46% ▼ −0.34% +0.14% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers